Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Recordati SpAMIL:REC -0.19%98 EV-to-EBIT is 17.40 as of Jul. 21, 2026, which is 15% below its 10-year median of 20.43. GuruFocus rates MIL:REC with a GF Score™ of 98/100 and a GF Value™ of €60.89 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 690 Drug Manufacturers companies, Recordati SpA ranks worse than 53.33% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Recordati SpA's Enterprise Value for the quarter that ended in Mar. 2026 was €11,963 Mil.
Recordati SpA's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €714 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recordati SpA EV-to-EBIT Related Terms
Recordati SpA EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Recordati SpA's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Recordati SpA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Recordati SpA's EV-to-EBIT falls into.
Recordati SpA's current Enterprise Value is €12,424 Mil.
Recordati SpA's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €714 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recordati SpA (MIL:REC) has a EV-to-EBIT of 17.40 as of Jul. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Recordati SpA and its competitors. This is 15% below median its historical median of 20.43. Over the past decade, Recordati SpA's EV-to-EBIT has ranged from 14.56 to 28.73. According to the industry distribution chart, Recordati SpA ranks #368 out of 690 companies in the Drug Manufacturers industry, placing it in the top 53.3%.
Is Recordati SpA's EV-to-EBIT too high?
Recordati SpA's current EV-to-EBIT of 17.40 is 15% below median its 10-year median of 20.43. Over the past 10 years, this metric has ranged from a low of 14.56 to a high of 28.73. The Drug Manufacturers industry median EV-to-EBIT is 15.84. Recordati SpA's value of 17.40 is 9.8% above this industry median. Based on the distribution chart, Recordati SpA ranks #368 out of 690 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Recordati SpA has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's EV-to-EBIT compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #368 out of 690 companies for EV-to-EBIT. This places Recordati SpA in the lower half of its industry. The industry median EV-to-EBIT is 15.84. Recordati SpA's value of 17.40 is 9.8% above this benchmark. Historically, Recordati SpA's own EV-to-EBIT has ranged from 14.56 to 28.73 over the past decade. While the company's 10-year median is 20.43 vs. the industry median of 15.84, Recordati SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.84, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recordati SpA's current EV-to-EBIT of 17.40 is 9.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Recordati SpA and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current EV-to-EBIT is 17.40, which is 15% below median its own 10-year median of 20.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €60.89, compared to a current price of €51.30 — trading 15.7% below its estimated fair value. The current EV-to-EBIT is 17.40, which is 15% below median its 10-year median of 20.43 and 9.8% above the Drug Manufacturers industry median of 15.84. Recordati SpA's overall GF Score™ is 98/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current EV-to-EBIT is 17.40 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MIL:REC) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of €51.30 is trading 15.7% below its estimated GF Value™ of €60.89.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MIL:REC:
EV-to-EBIT: 17.40 (15% below median its 10-year median of 20.43)
GF Value™: €60.89 vs. price of €51.30 (15.7% below fair value)
Industry Position: 9.8% above the Drug Manufacturers median (#368 of 690)
No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
98GF Score
Get the complete analysis for MIL:REC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:REC has been successfully added to your 
